At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 340 enrolled
Drug / intervention
Beclomethasone dipropionate +1 moredrug
Likely dose
Beclomethasone dipropionate 320 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Dec 3, 2009·Updated Dec 3, 2021
In Brief
A Phase 3 clinical trial evaluating Beclomethasone dipropionate and Placebo Nasal Aerosol for Seasonal Allergic Rhinitis and Hay Fever. Completed, enrolled 340 participants across 4 sites.
Detailed Summary
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis, Hay Fever
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartDec 2009
Primary CompletionFeb 2010
TodayJul 2026
First PostedDec 3, 2009
Enrollment StartDec 31, 2009
Primary CompletionFeb 28, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.6 years ago
Interventions
Beclomethasone dipropionatedrug
Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
Placebo Nasal Aerosoldrug
Placebo nasal aerosol administered each morning for two weeks.